Bioversys AG Total Assets
Bioversys AG total assets. Based on the latest financial reports, Bioversys AG (BIOV) holds total assets worth CHF76.91 Million CHF (≈ $97.23 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market value of Bioversys AG for the company's overall valuation and market capitalisation.
Total Assets of Bioversys AG (2024–2025)
Total assets of Bioversys AG from 2024 to 2025. This chart illustrates how Bioversys AG's total assets have evolved over time, based on quarterly financial data. See Bioversys AG stock price for real-time trading data and today's change.
Bioversys AG - Asset Composition Analysis
Bioversys AG Total Assets Breakdown (December 2025)
Bioversys AG total assets breakdown as of December 2025. Bioversys AG's total assets of CHF76.91 Million consist of 99.2% current assets and 0.8% non-current assets.
| Asset Category | Amount (CHF) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CHF0.00 | 91.0% |
| Accounts Receivable | CHF0.00 | 0.0% |
| Inventory | CHF0.00 | 0.0% |
| Property, Plant & Equipment | CHF0.00 | 0.0% |
| Intangible Assets | CHF0.00 | 0.0% |
| Goodwill | CHF0.00 | 0.0% |
Asset Composition Trend (2024–2025)
This chart illustrates how Bioversys AG's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore BIOV current assets to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bioversys AG's current assets represent 99.2% of total assets in 2025, an increase from 98.4% in 2024.
- Cash Position: Cash and equivalents constituted 91.0% of total assets in 2025, up from 76.2% in 2024.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2024.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Bioversys AG Competitors by Total Assets
Key competitors of Bioversys AG based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Bioversys AG - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.86 | 9.24 | 3.56 |
| Quick Ratio | 7.86 | 9.24 | 3.56 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CHF66.30 Million | CHF84.08 Million | CHF24.73 Million |
Bioversys AG - Advanced Valuation Insights
This section examines the relationship between Bioversys AG's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.59 |
| Latest Market Cap to Assets Ratio | 1.76 |
| Asset Growth Rate (YoY) | 159.3% |
| Total Assets | CHF90.64 Million |
| Market Capitalization | $159.24 Million USD |
Valuation Analysis
Above Book Valuation: The market values Bioversys AG's assets above their book value (1.76x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Bioversys AG's assets grew by 159.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Bioversys AG (2024–2025)
The table below shows the annual total assets of Bioversys AG from 2024 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CHF90.64 Million ≈ $114.59 Million |
+159.29% |
| 2024-12-31 | CHF34.96 Million ≈ $44.19 Million |
-- |
About Bioversys AG
BioVersys AG researches and develops antimicrobial drugs for bacterial infections. It develops BV100 that is in Phase 3 clinical trial for carbapenem-resistant Acinetobacter baumannii lung and bloodstream infections. The company is also developing Alpibectir, which is in Phase 2 clinical trial for the treatment of pulmonary and meningeal tuberculosis; BV200 to treat patients with Gram-positive S.… Read more